pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·17h ago·1 min read
save

China NewCo model pioneer sued in US over alleged trade secret theft and double-dealing

Sep 24, 2026·read at Fierce Biotech ↗Negative

A lawsuit filed in New York and later moved to federal court accuses Su Zhang, a consultant known for shaping the China "NewCo" dealmaking model, of misusing trade secrets and engaging in double-dealing.

Lepu Medical Technology says Zhang, while serving as its primary liaison for a portfolio of obesity and metabolic disease candidates, secretly held the chief business officer role at rival BrightGene Pharmaceutical and failed to disclose the conflict. The complaint also notes that Zhang's firm, CoDevCo, pursued transaction-based success fees from Lepu through arbitration in Singapore.

Lepu is seeking repayment of a $500,000 retainer, disgorgement of any benefits Zhang received from the alleged breaches, and additional damages.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing”

read at Fierce Biotech ↗
1,316 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVOOVERSEAS
drugs
Obesity4Type 2 Diabetes
topics
Obesity5GLP-1 receptor4Endocrinology & Metabolism2GIP receptor2Type 2 Diabetes2Hepatology

related stories

  • 2d agoNovo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzBioSpace
  • 2d agoNovo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030BioSpace
  • 3d agoRoche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trialBioSpace
  • 4d agoNovo’s plan to hit $23B in revenue by 2035 leaves investors wantingBioSpace
  • Aug 28Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist MounjaroBioSpace